Measuring the Comparative and Competitive Advantage of Iraqi Dates Production Using the Policy Analysis Matrix

Purpose: This study came to analyze the impact of government intervention in the production of this important crop and to determine the extent of its global competition and whether it has a comparative advantage in its production or not.   Theoretical framework: Dates are the most prominent representative of Iraq's foreign trade of commodities and agricultural products, which requires attention to that identity of Iraqi agriculture abroad. Interest in producing dates and improving their performance at the local and international levels is a necessity to revive the national economy and the agricultural economy alike.   Design/Methodology/Approach: The research aimed to measure the impact of agricultural government intervention in the production and export of Iraqi dates through the study of the Policy Analysis Matrix (PAM) and protection coefficients, and some macro policies related to the subject of the study.   Findings: The key finding of this research was the results of the policy analysis matrix for one acre of dates both showed that the selling prices of dates at the local level are lower than their prices at the global level, and this is what prompts farmers to export dates. It appeared through the commodity system has the ability to compete locally, but at lower levels than what is achieved at the level of social prices. Research, practical and social implications: This study contributes to analysis the impact of government intervention in the production of IRAQI DATES crop and to determine the extent of its global competition.   Originality/Value: The study recommends that the state should support the producers of dates and provides them with the necessary production requirements such as fertilizers, pesticides, fuel and others, and encourage the cultivation of high-quality and abundantly produced varieties and the introduction of modern technologies in this field. This maintains price stability

THE PROTEIN PROFILING OF ASIAN GIANT TOAD SKIN SECRETIONS AND THEIR ANTIMICROBIAL ACTIVITY

Objective: The skin secretions of toads are a rich source of bioactive peptides and proteins, which offer a wide range of therapeutic application. The current study was designed to elucidate the antimicrobial activity of Bufo asper skin secretions.Methods: Proteomic analysis of electrically stimulated skin secretions were mapped using SDS-PAGE followed by LC-MS/MS. In total,>50 proteins were identified with a molecular weight ranging from 20 to 250 KDa. The antimicrobial activity was performed by an agar-well diffusion method to measure the diameter of inhibition zone (DIZ) as well as microdilution technique to determine the minimum inhibitory concentration (MIC).Results: Toad's skin secretion (TSS) exhibited broad spectrum growth inhibitory activity against both Gram-positive and Gram-negative bacteria; with more pronounce activity towards Staphylococcus aureus and Bacillus subtilis, with MIC 12.25±0.4 and 25±1.3 μg/ml, respectively. Moreover, the proteomic profile of Bufo asper skin secretion has revealed the presence of interesting proteins such as, actin, histone H4 and heat shock proteins (HSP90, HSP70 and HSC70).Conclusion: we anticipate that the collective functions of proteins and peptides with a wide range of diversity may contribute to the TSS antimicrobial activity.Keywords: Bufo asper, Skin secretion, Antimicrobial, Proteomics

Do People Live at Sea Level and the Dead Sea Level Have Different Patterns of Anti-Hypertensive Drugs

Background: people live at various areas of sea level may have different patterns of anti-hypertensive drugs. Such a relation has never been reported in Jordan. Study objectives: the current study investigated how the sea level will impact the prevalence of hypertension in these areas, and how will affect the pharmacological properties of such a population. Methodology: a cross-sectional study design was involved to collect data from study participants. A total of 1000 participants were randomly selected from the two study areas. 500 participants from each. Participants were matched for age and gender. Blood pressure were measured for all participants. Blood samples were withdrawn to investigate the level of angiotensin II. Data was collected through organizing a working excel sheet and was further analyzed through using SPSS version 20. Data was presented as means, standard deviations, frequencies and percentages. The relationships between variables were examined using independent T-test. Significance was measured at an alpha < 0.05. Study findings: the main findings of the present study were that the mean of SBP is significantly higher in the Dead Sea (122.42±10.53 mmHg) than the Sea level area (118.07±11.64 mmHg), (p=0.001). Another significant variable was MBP which its mean was 91.64 ± 8.90 mmHg in the Dead Sea and 89.84 ± 8.72 mm Hg. The difference in the mean was statistically significant (p=0.001). The level of angiotensin II was 8.84 ± 4.65pg/ml in the Dead Sea area and 11.21± 6.05pg/ml in the area of the Sea level. The difference in the mean of the two study areas was not statistically significant (p>0.05). Conclusions: although the level of angiotensin II was not significantly varied between the study areas, but its trend was to be higher in the Sea level area. It was surprised to have higher levels of SBP and MBP in the Dead Sea rather than the Seal level area. It can be implied that the therapeutic options of hypertensive drugs follow different patterns independent of angiotensin II pathways

PUTRAFLEX: UPM flexible curriculum

PUTRAFLEX is structured with an underpinning philosophy of producing Future-Proof PUTRA Graduates through a curriculum that is flexible in nature, promotes the convergence of disciplines, and offers diverse study paths. Accordingly, PUTRAFLEX contains the concepts and guidelines for its implementation at UPM

The evolving SARS-CoV-2 epidemic in Africa: Insights from rapidly expanding genomic surveillance

INTRODUCTION Investment in Africa over the past year with regard to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) sequencing has led to a massive increase in the number of sequences, which, to date, exceeds 100,000 sequences generated to track the pandemic on the continent. These sequences have profoundly affected how public health officials in Africa have navigated the COVID-19 pandemic. RATIONALE We demonstrate how the first 100,000 SARS-CoV-2 sequences from Africa have helped monitor the epidemic on the continent, how genomic surveillance expanded over the course of the pandemic, and how we adapted our sequencing methods to deal with an evolving virus. Finally, we also examine how viral lineages have spread across the continent in a phylogeographic framework to gain insights into the underlying temporal and spatial transmission dynamics for several variants of concern (VOCs). RESULTS Our results indicate that the number of countries in Africa that can sequence the virus within their own borders is growing and that this is coupled with a shorter turnaround time from the time of sampling to sequence submission. Ongoing evolution necessitated the continual updating of primer sets, and, as a result, eight primer sets were designed in tandem with viral evolution and used to ensure effective sequencing of the virus. The pandemic unfolded through multiple waves of infection that were each driven by distinct genetic lineages, with B.1-like ancestral strains associated with the first pandemic wave of infections in 2020. Successive waves on the continent were fueled by different VOCs, with Alpha and Beta cocirculating in distinct spatial patterns during the second wave and Delta and Omicron affecting the whole continent during the third and fourth waves, respectively. Phylogeographic reconstruction points toward distinct differences in viral importation and exportation patterns associated with the Alpha, Beta, Delta, and Omicron variants and subvariants, when considering both Africa versus the rest of the world and viral dissemination within the continent. Our epidemiological and phylogenetic inferences therefore underscore the heterogeneous nature of the pandemic on the continent and highlight key insights and challenges, for instance, recognizing the limitations of low testing proportions. We also highlight the early warning capacity that genomic surveillance in Africa has had for the rest of the world with the detection of new lineages and variants, the most recent being the characterization of various Omicron subvariants. CONCLUSION Sustained investment for diagnostics and genomic surveillance in Africa is needed as the virus continues to evolve. This is important not only to help combat SARS-CoV-2 on the continent but also because it can be used as a platform to help address the many emerging and reemerging infectious disease threats in Africa. In particular, capacity building for local sequencing within countries or within the continent should be prioritized because this is generally associated with shorter turnaround times, providing the most benefit to local public health authorities tasked with pandemic response and mitigation and allowing for the fastest reaction to localized outbreaks. These investments are crucial for pandemic preparedness and response and will serve the health of the continent well into the 21st century

Hibiscus sabdariffa, a Treatment for Uncontrolled Hypertension. Pilot Comparative Intervention

In Iraq, in 2019, there were about 1.4 million Internally Displaced Persons (IDP); medical treatments were often interrupted. The feasibility of using Hibiscus sabdariffa (HS) decoction to curb hypertension was evaluated. A multicentric comparative pilot intervention for 121 participants with high blood pressure (BP) (≥140/90 mmHg) was conducted. Participants of the intervention group (with or without conventional medication) received HS decoction on a dose regimen starting from 10 grams per day. BP was measured five times over six weeks. The major active substances were chemically quantified. Results: After 6 weeks, 61.8% of participants from the intervention group (n = 76) reached the target BP < 140/90 mmHg, compared to 6.7% in the control group (n = 45). In the intervention group, a mean (±SD) reduction of 23.1 (±11.8) mmHg and 12.0 (±11.2) for systolic and diastolic BP, respectively, was observed, while in the control group the reduction was 4.4 (±10.2)/3.6 (±8.7). The chemical analysis of the starting dose indicated a content of 36 mg of total anthocyanins and 2.13 g of hibiscus acid. The study shows the feasibility of using HS decoction in IDP’s problematic framework, as hibiscus is a safe, local, affordable, and culturally accepted food product

Empagliflozin in Patients with Chronic Kidney Disease

Background The effects of empagliflozin in patients with chronic kidney disease who are at risk for disease progression are not well understood. The EMPA-KIDNEY trial was designed to assess the effects of treatment with empagliflozin in a broad range of such patients. Methods We enrolled patients with chronic kidney disease who had an estimated glomerular filtration rate (eGFR) of at least 20 but less than 45 ml per minute per 1.73 m(2) of body-surface area, or who had an eGFR of at least 45 but less than 90 ml per minute per 1.73 m(2) with a urinary albumin-to-creatinine ratio (with albumin measured in milligrams and creatinine measured in grams) of at least 200. Patients were randomly assigned to receive empagliflozin (10 mg once daily) or matching placebo. The primary outcome was a composite of progression of kidney disease (defined as end-stage kidney disease, a sustained decrease in eGFR to < 10 ml per minute per 1.73 m(2), a sustained decrease in eGFR of & GE;40% from baseline, or death from renal causes) or death from cardiovascular causes. Results A total of 6609 patients underwent randomization. During a median of 2.0 years of follow-up, progression of kidney disease or death from cardiovascular causes occurred in 432 of 3304 patients (13.1%) in the empagliflozin group and in 558 of 3305 patients (16.9%) in the placebo group (hazard ratio, 0.72; 95% confidence interval [CI], 0.64 to 0.82; P < 0.001). Results were consistent among patients with or without diabetes and across subgroups defined according to eGFR ranges. The rate of hospitalization from any cause was lower in the empagliflozin group than in the placebo group (hazard ratio, 0.86; 95% CI, 0.78 to 0.95; P=0.003), but there were no significant between-group differences with respect to the composite outcome of hospitalization for heart failure or death from cardiovascular causes (which occurred in 4.0% in the empagliflozin group and 4.6% in the placebo group) or death from any cause (in 4.5% and 5.1%, respectively). The rates of serious adverse events were similar in the two groups. Conclusions Among a wide range of patients with chronic kidney disease who were at risk for disease progression, empagliflozin therapy led to a lower risk of progression of kidney disease or death from cardiovascular causes than placebo

Rivaroxaban with or without aspirin in stable cardiovascular disease

BACKGROUND: We evaluated whether rivaroxaban alone or in combination with aspirin would be more effective than aspirin alone for secondary cardiovascular prevention. METHODS: In this double-blind trial, we randomly assigned 27,395 participants with stable atherosclerotic vascular disease to receive rivaroxaban (2.5 mg twice daily) plus aspirin (100 mg once daily), rivaroxaban (5 mg twice daily), or aspirin (100 mg once daily). The primary outcome was a composite of cardiovascular death, stroke, or myocardial infarction. The study was stopped for superiority of the rivaroxaban-plus-aspirin group after a mean follow-up of 23 months. RESULTS: The primary outcome occurred in fewer patients in the rivaroxaban-plus-aspirin group than in the aspirin-alone group (379 patients [4.1%] vs. 496 patients [5.4%]; hazard ratio, 0.76; 95% confidence interval [CI], 0.66 to 0.86; P<0.001; z=−4.126), but major bleeding events occurred in more patients in the rivaroxaban-plus-aspirin group (288 patients [3.1%] vs. 170 patients [1.9%]; hazard ratio, 1.70; 95% CI, 1.40 to 2.05; P<0.001). There was no significant difference in intracranial or fatal bleeding between these two groups. There were 313 deaths (3.4%) in the rivaroxaban-plus-aspirin group as compared with 378 (4.1%) in the aspirin-alone group (hazard ratio, 0.82; 95% CI, 0.71 to 0.96; P=0.01; threshold P value for significance, 0.0025). The primary outcome did not occur in significantly fewer patients in the rivaroxaban-alone group than in the aspirin-alone group, but major bleeding events occurred in more patients in the rivaroxaban-alone group. CONCLUSIONS: Among patients with stable atherosclerotic vascular disease, those assigned to rivaroxaban (2.5 mg twice daily) plus aspirin had better cardiovascular outcomes and more major bleeding events than those assigned to aspirin alone. Rivaroxaban (5 mg twice daily) alone did not result in better cardiovascular outcomes than aspirin alone and resulted in more major bleeding events